Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F21%3A00078575" target="_blank" >RIV/00209805:_____/21:00078575 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/21:00121828

Výsledek na webu

<a href="https://www.mdpi.com/2072-6694/13/7/1586" target="_blank" >https://www.mdpi.com/2072-6694/13/7/1586</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers13071586" target="_blank" >10.3390/cancers13071586</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

Popis výsledku v původním jazyce

Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a median follow-up of 36 months evaluated the role of adding platinum salts into standard neoadjuvant chemotherapy (NACT). After the initial four standard NACT cycles, early clinical response (ECR) was assessed and used to identify tumors and patients generally sensitive to NACT. BRCA1/2 mutation, smaller unifocal tumors, and Ki-67 GREATER-THAN OR EQUAL TO 65% were independent predictors of ECR. The total pCR rate was 41%, the achievement of pCR was strongly associated with ECR (OR = 15.1, p &lt; 0.001). According to multivariable analysis, the significant benefit of platinum NACT was observed in early responders GREATER-THAN OR EQUAL TO45 years, Ki-67 GREATER-THAN OR EQUAL TO 65% and persisted lymph node involvement regardless of BRCA1/2 status. Early responders with pCR had a longer time to death (HR = 0.28, p &lt; 0.001) and relapse (HR = 0.26, p &lt; 0.001). The pCR was achieved in only 7% of non-responders. However, platinum salts favored non-responders&apos; survival outcomes without statistical significance. Toxicity was significantly often observed in patients with platinum NACT (p = 0.003) but not for grade 3/4 (p = 0.155). These results based on real-world evidence point to the usability of ECR in NACT management, especially focusing on the benefit of platinum salts.

Název v anglickém jazyce

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

Popis výsledku anglicky

Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a median follow-up of 36 months evaluated the role of adding platinum salts into standard neoadjuvant chemotherapy (NACT). After the initial four standard NACT cycles, early clinical response (ECR) was assessed and used to identify tumors and patients generally sensitive to NACT. BRCA1/2 mutation, smaller unifocal tumors, and Ki-67 GREATER-THAN OR EQUAL TO 65% were independent predictors of ECR. The total pCR rate was 41%, the achievement of pCR was strongly associated with ECR (OR = 15.1, p &lt; 0.001). According to multivariable analysis, the significant benefit of platinum NACT was observed in early responders GREATER-THAN OR EQUAL TO45 years, Ki-67 GREATER-THAN OR EQUAL TO 65% and persisted lymph node involvement regardless of BRCA1/2 status. Early responders with pCR had a longer time to death (HR = 0.28, p &lt; 0.001) and relapse (HR = 0.26, p &lt; 0.001). The pCR was achieved in only 7% of non-responders. However, platinum salts favored non-responders&apos; survival outcomes without statistical significance. Toxicity was significantly often observed in patients with platinum NACT (p = 0.003) but not for grade 3/4 (p = 0.155). These results based on real-world evidence point to the usability of ECR in NACT management, especially focusing on the benefit of platinum salts.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/LM2018125" target="_blank" >LM2018125: Banka klinických vzorků</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancers

ISSN

2072-6694

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

19

Strana od-do

1586

Kód UT WoS článku

000638335700001

EID výsledku v databázi Scopus

2-s2.0-85103267338